Effect of GLP-1 receptor agonist exenatide on endothelial dysfunction associated with hyperhomocysteinemia in type 2 diabetes
Description: Incidence of Type 2 diabetes in Hong Kong has reached to around 10% in the general population, due to factors like aging, dietary change, sedentary lifestyle, and psycho-economical stress. Type 2 diabetic patients have high risk of cardiovascular events. Endothelial cell dysfunction is an early event in the development of diabetic macro-vascular complications. Elevated plasma homocysteine level (hyperhomocysteinemia) impairs endothelial cell function by inducing endoplasmic reticulum stress and oxidative stress. Hyperhomocysteinemia is also an independent predictor for retinopathy, nephropathy, and coronary heart disease in type 2 diabetic patients. Glucagon like peptide-1 receptor agonists such as exenatide are incretin mimetics for improving glycemic control in type 2 diabetic patients. Emerging evidences show that GLP-1R agonists have direct effect on the cardiovascular system. However, the effect and the mechanism mediating the vascular benefits of GLP-1R agonist in type 2 diabetes remains unclear. We aim at investigating whether exenatide and other GLP-1R agonists protects against homocysteine-induced endothelial dysfunction in type 2 diabetes. We will first examine the effect of GLP-1R agonists to ameliorate endothelial dysfunction in isolated arteries and endothelial cells induced by homocysteine and hyperglycemia. We will then evaluate the effect of exenatide treatment in type 2 diabetic mouse model with elevated plasma homocysteine. We will also study the association between homocysteine level and cardiovascular risk factors in type 2 diabetic patients before and after GLP-1R agonists treatment. Our study shall provide valuable insights supporting the use of GLP-1R agonists in type 2 diabetic patients for additional benefit of reducing diabetic vasculopathy.
Funder: Health and Medical Research Fund
Amount: HKD 947,600
Funding type: grant
Funder scheme: HMRF - Advanced Medical Research
Start date: 2016-01-01
Investigator: Xiaoyu TIAN (lead)
Institutions: Chinese University of Hong Kong, School of Biomedical Sciences, The Chinese University of Hong Kong
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Funded outputs count: 7
Funder award ID: 05162906
OpenAlex ID: G4206103345
